Literature DB >> 26474593

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Corey A Scipione1, Sera E Sayegh1, Rocco Romagnuolo1, Sotirios Tsimikas2, Santica M Marcovina3, Michael B Boffa1, Marlys L Koschinsky4.   

Abstract

Elevated lipoprotein (a) [Lp(a)] levels are a causal risk factor for coronary heart disease. Accumulating evidence suggests that Lp(a) can stimulate cellular inflammatory responses through the kringle-containing apolipoprotein (a) [apo(a)] component. Here, we report that recombinant apo(a) containing 17 kringle (17K) IV domains elicits a dose-dependent increase in interleukin (IL)-8 mRNA and protein expression in THP-1 and U937 macrophages. This effect was blunted by mutation of the lysine binding site in apo(a) kringle IV type 10, which resulted in the loss of oxidized phospholipid (oxPL) on apo(a). Trypsin-digested 17K had the same stimulatory effect on IL-8 expression as intact apo(a), while enzymatic removal of oxPL from apo(a) significantly blunted this effect. Using siRNA to assess candidate receptors, we found that CD36 and TLR2 may play roles in apo(a)-mediated IL-8 stimulation. Downstream of these receptors, inhibitors of MAPKs, Jun N-terminal kinase and ERK1/2, abolished the effect of apo(a) on IL-8 gene expression. To assess the roles of downstream transcription factors, luciferase reporter gene experiments were conducted using an IL-8 promoter fragment. The apo(a)-induced expression of this reporter construct was eliminated by mutation of IL-8 promoter binding sites for either NF-κB or AP-1. Our results provide a mechanistic link between oxPL modification of apo(a) and stimulation of proinflammatory intracellular signaling pathways.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  apolipoprotein (a); atherosclerosis; inflammation; interleukin-8; lipoprotein (a)

Mesh:

Substances:

Year:  2015        PMID: 26474593      PMCID: PMC4655984          DOI: 10.1194/jlr.M060210

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

Review 1.  Toll-like receptors and their ligands.

Authors:  G M Barton; R Medzhitov
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  Efficient non-viral transfection of THP-1 cells.

Authors:  Michael Schnoor; Insa Buers; Anika Sietmann; Martin F Brodde; Oliver Hofnagel; Horst Robenek; Stefan Lorkowski
Journal:  J Immunol Methods       Date:  2009-04-05       Impact factor: 2.303

3.  TNFalpha- and NF-kappaB-dependent induction of the chemokine CCL1 in human macrophages exposed to the atherogenic lipoprotein(a).

Authors:  Monique N'Diaye; Eric Le Ferrec; Florian Kronenberg; Hans Dieplinger; Marc Le Vee; Olivier Fardel
Journal:  Life Sci       Date:  2009-02-02       Impact factor: 5.037

4.  IL-8 is an angiogenic factor in human coronary atherectomy tissue.

Authors:  A Simonini; M Moscucci; D W Muller; E R Bates; F D Pagani; M D Burdick; R M Strieter
Journal:  Circulation       Date:  2000-04-04       Impact factor: 29.690

5.  Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain.

Authors:  O Klezovitch; C Edelstein; A M Scanu
Journal:  J Biol Chem       Date:  2001-10-08       Impact factor: 5.157

Review 6.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 7.  Chemokines in atherosclerosis: an update.

Authors:  Alma Zernecke; Erdenechimeg Shagdarsuren; Christian Weber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

Review 8.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

9.  Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.

Authors:  Sotirios Tsimikas; Paul Clopton; Emmanouil S Brilakis; Santica M Marcovina; Amit Khera; Elizabeth R Miller; James A de Lemos; Joseph L Witztum
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

10.  Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids.

Authors:  Monika Sharma; Anne Von Zychlinski-Kleffmann; Carolyn M Porteous; Gregory T Jones; Michael J A Williams; Sally P A McCormick
Journal:  J Lipid Res       Date:  2015-04-06       Impact factor: 5.922

View more
  24 in total

1.  Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.

Authors:  Calvin Yeang; Devin Hasanally; Xuchu Que; Ming-Yow Hung; Aleksandra Stamenkovic; David Chan; Rakesh Chaudhary; Victoria Margulets; Andrea L Edel; Masahiko Hoshijima; Yusu Gu; William Bradford; Nancy Dalton; Phuong Miu; David Yc Cheung; Davinder S Jassal; Grant N Pierce; Kirk L Peterson; Lorrie A Kirshenbaum; Joseph L Witztum; Sotirios Tsimikas; Amir Ravandi
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

2.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

3.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

Authors:  Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes
Journal:  Circulation       Date:  2016-08-05       Impact factor: 29.690

4.  Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.

Authors:  Sony Tuteja; Lu Wang; Richard L Dunbar; Jinbo Chen; Stephanie DerOhannessian; Santica M Marcovina; Marshall Elam; Ellis Lader; Daniel J Rader
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

5.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

Review 6.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

7.  LPA Gene, Ethnicity, and Cardiovascular Events.

Authors:  Sang-Rok Lee; Anand Prasad; Yun-Seok Choi; Chao Xing; Paul Clopton; Joseph L Witztum; Sotirios Tsimikas
Journal:  Circulation       Date:  2016-11-09       Impact factor: 29.690

Review 8.  Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Authors:  Sotirios Tsimikas
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

9.  Interleukins 6 and 8 and abdominal fat depots are distinct correlates of lipid moieties in healthy pre- and postmenopausal women.

Authors:  Johannes D Veldhuis; Roy B Dyer; Sergey A Trushin; Olga P Bondar; Ravinder J Singh; George G Klee
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

Review 10.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.